A

Assertio Holdings Inc
NASDAQ:ASRT

Watchlist Manager
Assertio Holdings Inc
NASDAQ:ASRT
Watchlist
Price: 0.98 USD 0.1%
Market Cap: 93.4m USD
Have any thoughts about
Assertio Holdings Inc?
Write Note

Assertio Holdings Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Assertio Holdings Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
A
Assertio Holdings Inc
NASDAQ:ASRT
Accrued Liabilities
$74m
CAGR 3-Years
5%
CAGR 5-Years
-6%
CAGR 10-Years
5%
Johnson & Johnson
NYSE:JNJ
Accrued Liabilities
$33.5B
CAGR 3-Years
4%
CAGR 5-Years
8%
CAGR 10-Years
10%
Bristol-Myers Squibb Co
NYSE:BMY
Accrued Liabilities
$13.3B
CAGR 3-Years
10%
CAGR 5-Years
16%
CAGR 10-Years
15%
Pfizer Inc
NYSE:PFE
Accrued Liabilities
$2.6B
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Accrued Liabilities
$15.7B
CAGR 3-Years
3%
CAGR 5-Years
6%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Accrued Liabilities
$14.1B
CAGR 3-Years
21%
CAGR 5-Years
19%
CAGR 10-Years
18%
No Stocks Found

Assertio Holdings Inc
Glance View

Market Cap
93.5m USD
Industry
Pharmaceuticals

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.

ASRT Intrinsic Value
1.56 USD
Undervaluation 37%
Intrinsic Value
Price
A

See Also

What is Assertio Holdings Inc's Accrued Liabilities?
Accrued Liabilities
74m USD

Based on the financial report for Sep 30, 2024, Assertio Holdings Inc's Accrued Liabilities amounts to 74m USD.

What is Assertio Holdings Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
5%

Over the last year, the Accrued Liabilities growth was -9%. The average annual Accrued Liabilities growth rates for Assertio Holdings Inc have been 5% over the past three years , -6% over the past five years , and 5% over the past ten years .

Back to Top